Significance Measles virus (MeV) vaccine is one of the safest and most efficient vaccines with a track record in children. Here, we generated a panel of rMeV-based vaccines with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) S antigens inserted near 3′ of the MeV genome. The rMeV expressing a soluble stabilized, prefusion spike (preS) is much more potent in triggering SARS-CoV-2–specific neutralizing antibody than rMeV-based full-length S vaccine candidate. A single dose of rMeV-preS is sufficient to induce high levels of SARS-CoV-2 antibody in animals. Furthermore, rMeV-preS induces high levels of Th1-biased immunity. Hamsters immunized with rMeV-preS were completely protected against SARS-CoV-2 challenge. Our results demonstrate rMeV-preS is a safe and highly efficacious bivalent vaccine candidate for SARS-CoV-2 and MeV. The current pandemic of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) highlights an urgent need to develop a safe, efficacious, and durable vaccine. Using a measles virus (rMeV) vaccine strain as the backbone, we developed a series of recombinant attenuated vaccine candidates expressing various forms of the SARS-CoV-2 spike (S) protein and its receptor binding domain (RBD) and evaluated their efficacy in cotton rat, IFNAR −/− mice, IFNAR −/− -hCD46 mice, and golden Syrian hamsters. We found that rMeV expressing stabilized prefusion S protein (rMeV-preS) was more potent in inducing SARS-CoV-2–specific neutralizing antibodies than rMeV expressing full-length S protein (rMeV-S), while the rMeVs expressing different lengths of RBD (rMeV-RBD) were the least potent. Animals immunized with rMeV-preS produced higher levels of neutralizing antibody than found in convalescent sera from COVID-19 patients and a strong Th1-biased T cell response. The rMeV-preS also provided complete protection of hamsters from challenge with SARS-CoV-2, preventing replication in lungs and nasal turbinates, body weight loss, cytokine storm, and lung pathology. These data demonstrate that rMeV-preS is a safe and highly efficacious vaccine candidate, supporting its further development as a SARS-CoV-2 vaccine.
【저자키워드】 SARS-CoV-2 vaccine, measles virus vector, prefusion spike, 【초록키워드】 neutralizing antibody, SARS-CoV-2, Efficacy, Vaccine, Cytokine storm, coronavirus, Immunity, Neutralizing antibodies, hamsters, body weight, children, Genome, lung, cytokine, severe acute respiratory syndrome Coronavirus, virus, SARS-CoV-2 vaccine, Receptor binding domain, Replication, Protein, T cell, SARS-CoV-2 antibody, mice, animals, RBD, animal, Lungs, vaccine candidate, hamster, respiratory, T cell response, convalescent sera, S antigen, COVID-19 patients, single dose, SARS-CoV-2 spike, Lung pathology, measles virus, COVID-19 patient, attenuated vaccine, Safe, Cotton rat, nasal turbinates, weight loss, acute respiratory syndrome, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, These data, IFNAR, prefusion, backbone, vaccine strain, pandemic of COVID-19, Body weight loss, full-length S protein, full-length S, triggering, Complete, immunized, highlight, produced, develop, caused, evaluated, form, provided, induce, expressing, prefusion S, Significance, the SARS-CoV-2, 【제목키워드】 SARS-CoV-2, Vaccine, Safe, prefusion, expressing,